ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14, 2025
By Adare Pharmaceuticals
Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.
This paper presents an analysis of the growing global obesity epidemic and the significant healthcare and economic burdens it creates. It highlights GLP-1 analogs, particularly in oral formulations, as a promising new treatment strategy for weight loss and managing related conditions. The text outlines the challenges in delivering peptide-based drugs orally due to stomach degradation and poor intestinal absorption, and explores various technological advancements in formulation and drug delivery systems aimed at improving their stability, bioavailability, and efficacy. Finally, it discusses the expanding market for obesity treatments and the future of personalized medicine in this field.
Download the White Paper.
Audio Overview (Google NotebookLM)
(12 Minutes 30 Seconds)
